denosomin | 1185751-43-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: denosomin
• 英文别名: (2R)-2-[(1S)-1-[(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]-5-(hydroxymethyl)-2,3-dihydropyran-6-one
• CAS: 1185751-43-2
• 化学式: C₂₇H₄₀O₄
• 分子量: 428.612
• InChiKey: DDEPTGBPVOPQPT-BPFANPAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  [(2S,3R)-2-[(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hex-5-en-3-yl] 2-(hydroxymethyl)prop-2-enoate 在 Stewart-Grubbs催化剂 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以88%的产率得到denosomin
  参考文献：
  名称：

  Synthesis of Sominone and Its Derivatives Based on an RCM Strategy: Discovery of A Novel Anti-Alzheimer’s Disease Medicine Candidate “Denosomin”

  摘要：

  Synthesis of sominone was achieved starting from dehydroepiandrosterone on the basis of an RCM strategy for the construction of a delta-lactone side chain. This synthetic protocol was applied for the synthesis of several analogous derivatives including 1-deoxy-24-norsominone (denosomin), which was revealed to exhibit notable bioactivities for new antidementia chemotherapy, exceeding the original natural compound sominone.

  DOI：

  10.1021/ol901553w

文献信息

• [EN] NOVEL SOMINONE DERIVATIVE<br/>[FR] NOUVEAU DÉRIVÉ DE SOMINONE
  申请人：LEAD CHEM CO LTD

  公开号：WO2010041681A1

  公开（公告）日：2010-04-15

  【課題】神経疾患の予防治療剤として有用な新規化合物を提供することを目的とする。 【解決手段】次式（１）で表されるソミノン誘導体又はその塩。

  【问题】旨在提供作为神经疾病预防治疗药物的有用新化合物。 【解决方法】表示为式（1）的Somino衍生物或其盐。
• THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA;
  申请人：Resilio Company Limited

  公开号：EP2946792A1

  公开（公告）日：2015-11-25

  A primary objective is to provide a drug for radical cure and a therapeutic method for diseases associated with axonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, or brain contusion) based on the pathogenic mechanism thereof. Provided is a compound having a stimulating activity on 1,25D3-MARRS or a pharmaceutically acceptable salt thereof. Also provided is a technical idea relating to a pharmaceutical composition for disease treatment comprising a therapeutically effective amount thereof, a production method, a method for preventing or treating a disease, and a kit.

  其主要目的是根据轴突功能障碍的致病机制，提供一种根治与轴突功能障碍相关疾病（例如阿尔茨海默病、痴呆症、帕金森病、脊髓损伤或脑挫伤）的药物和治疗方法。 本发明提供了一种对 1,25D3-MARRS具有刺激活性的化合物或其药学上可接受的盐。还提供了一种技术构思，涉及一种包含治疗有效量的用于疾病治疗的药物组合物、一种生产方法、一种预防或治疗疾病的方法以及一种试剂盒。
• THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS
  申请人：RESILIO COMPANY LIMITED

  公开号：US20150126464A1

  公开（公告）日：2015-05-07

  A primary objective is to provide a drug for radical cure and a therapeutic method for diseases associated with axonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, or brain contusion) based on the pathogenic mechanism thereof. Provided is a compound having a stimulating activity on 1,25D 3 -MARRS or a pharmaceutically acceptable salt thereof. Also provided is a technical idea relating to a pharmaceutical composition for disease treatment comprising a therapeutically effective amount thereof, a production method, a method for preventing or treating a disease, and a kit.
• [EN] THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE<br/>[FR] AGENT THÉRAPEUTIQUE ET PROCÉDÉ THÉRAPEUTIQUE CONCERNANT 1,25D3-MARRS POUR UNE MALADIE NEUROLOGIQUE TELLE QUE LA MALADIE D'ALZHEIMER
  申请人：RESILIO COMPANY LTD

  公开号：WO2014112145A1

  公开（公告）日：2014-07-24

  　神経軸索の機能不全が関与する疾患（例えば、アルツハイマー病、認知症、パーキンソン病、脊髄損傷、脳挫傷等）の、病態の発症原因メカニズムに基づく根本療法剤の提供、及び治療法の提供を主な課題とする。　1,25D3-MARRSの刺激活性を有する化合物、又はその塩を提供する。さらに、その治療有効量を含む疾患の治療のための医薬組成物、製造法、疾患の予防又は治療方法、及びキットに関する技術思想を提供する。